Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance

PL Tzou, SY Rhee, D Descamps… - Journal of …, 2020 - academic.oup.com
Background Integrase strand transfer inhibitors (INSTIs) are expected to be widely adopted
globally, requiring surveillance of resistance emergence and transmission. Objectives We …

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

D Armenia, MM Santoro, C Charpentier… - Journal of …, 2023 - academic.oup.com
Background This work aims to evaluate integrase resistance and its predictors in HIV-1
infected combined antiretroviral therapy (cART) experienced individuals failing a …

[HTML][HTML] Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in …

J Fokam, AD Nka, FYM Dzukam, JE Gabisa, Y Bouba… - Medicine, 2023 - journals.lww.com
This study aimed to compare viral suppression (VS) between children, adolescents, and
adults in the frame of transition to dolutegravir (DTG)-based antiretroviral therapy (ART) in …

Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study

PK Cheung, A Shahid, W Dong, KJ Lepik… - Journal of …, 2022 - academic.oup.com
Background Routine HIV drug resistance genotyping identified an integrase sequence
harbouring T97A, E138K, G140S and Q148H, with high predicted resistance to all integrase …

Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings

D Armenia, Y Bouba, R Gagliardini, C Gori… - Journal of Clinical …, 2020 - Elsevier
Background Virological response and resistance profile were evaluated in drug-naïve
patients starting their first-line integrase inhibitors (INIs)-based regimen in a clinical setting …

[HTML][HTML] DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World …

S Sequera-Arquelladas, C Hidalgo-Tenorio… - Viruses, 2024 - mdpi.com
The continuous pharmacological advances in antiretroviral treatment (ART) and the
increasing understanding of HIV drug resistance has led to a change in the paradigm of ART …

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national …

AG Marcelin, C Charpentier, P Bellecave… - Journal of …, 2021 - academic.oup.com
Abstract Background Successful 2-drug regimens (2DRs) for HIV were made possible by the
availability of drugs combining potency and tolerability with a high genetic barrier to …

DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine

C Soulie, A Balde, D Fofana… - Journal of …, 2024 - academic.oup.com
Background Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has
a different resistance profile from first-generation NNRTIs. Our aim was to investigate the …

[HTML][HTML] Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches

D Vergni, D Santoni, Y Bouba, S Lemme… - Infection, Genetics and …, 2022 - Elsevier
This study aimed at updating previous data on HIV-1 integrase variability, by using effective
bioinformatics methods combining different statistical instruments from simple entropy and …

[HTML][HTML] Emergence of the G118R pan-integrase resistance mutation as a result of low compliance to a dolutegravir-based cART

H Mens, L Fjordside, J Fonager, J Gerstoft - Infectious disease reports, 2022 - mdpi.com
HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1
combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase …